Q-omics provides the consensus-scored GOLGA8DP profile across patient tissues and cancer cell-line models. GOLGA8DP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLGA8DP is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, GOLGA8DP RNA expression shows 8,370 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where GOLGA8DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8DP survival associations across molecular data types. GOLGA8DP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8DP RNA expression–survival associations across cancer types. High GOLGA8DP expression shows unfavorable associations in KIRC, CHOL, TGCT, HNSC and COAD, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLGA8DP RNA expression.
This table summarizes GOLGA8DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8DP shows lower tumor expression in BRCA and higher tumor expression in HNSC and LUSC. The BRCA box plot shows higher GOLGA8DP RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .006).
This table shows molecular features associated with GOLGA8DP in patient tissues and cancer cell lines. In patient samples, GOLGA8DP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
